Print E-mail
Volume 39, Number 4, August 2006

Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest


Yu-Shin Chiu, Shan-Chwen Chang, Po-Ren Hsueh, Jiun-Ling Wang, Hsin-Yun Sun, Yee-Chun Chen3
Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, Taipei; Division of Infectious Diseases, Min-Sheng General Hospital, Taoyuan; Department of Medicine, National Taiwan University College of Medicine, Taipei; and Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

Received: June 21, 2005    Revised: August 15, 2005    Accepted: August 26, 2005   

 

Corresponding author:

Yee-Chun Chen, M.D., Ph.D., Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. E-mail: ycc@ha.mc.ntu.edu.tw This e-mail address is being protected from spam bots, you need JavaScript enabled to view it



 

Background and purpose: 

The minimal inhibitory concentrations (MICs) of amphotericin B (AmB) determined by the National Committee for Clinical Laboratory Standards (NCCLS; NCCLS document M27-A) broth dilution method are in a relatively narrow ranges and this may lead to underestimation of the AmB-resistant rate in clinical isolates. We evaluated in vitro susceptibility of clinical isolates of Candida spp. to AmB using Etest and determined the distribution of AmB MICs in different species.

 



 

Methods:

We used the Etest (AB Biodisk, Solna , Sweden ) to evaluate the MICs of Candida isolates randomly collected during 2001-2003 in a teaching hospital.

 



 

Results:

Of the 572 isolates evaluated, Candida albicans (50.7%) was the most common species, followed by Candida tropicalis (23.9%), Candida parapsilosis (13.1%), Candida glabrata (9.4%), Candida krusei (1.9%), and Candida guilliermondii (0.9%). The majority of isolates were from blood (85%). The minimal concentrations of AmB required to inhibit 50%/90% of the isolates (MIC50/MIC90) were 0.19/0.38 µg/mL for C. krusei , 0.125/0.38 µg/mL for C. glabrata , 0.094/0.25 µg/mL for C. tropicalis , 0.032/0.19 µg/mL for C. albicans , 0.016/0.125 µg/mL for C. parapsilosis , and 0.023/0.032 µg/mL for C. guilliermondii . Only 1 blood isolate of C. glabrata was resistant to AmB (MIC ≥ 1 µg/mL) [0.17%]. 18.2% of isolates were less susceptible to AmB (MIC ≥ 0.19 µg/mL) with the highest rates for C. krusei (63.6 %), followed by C. glabrata (37.0%), C. tropicalis (29.9%), C. albicans (11.0%), C. parapsilosis (5.3%), and C. guilliermondii (0%). More isolates collected from patients with hematologic malignancy were less susceptible to AmB than those collected from those with other diseases (30.5% vs 15.4%, p<0.05).

 



 

Conclusion:

This study demonstrated that AmB resistance remains rare at this hospital in Candida clinical isolates despite increasing use of this agent during the past 4 decades.

 



 

Key words:

Amphotericin B, Candida , fungal drug resistance, microbial sensitivity tests


 



 

J Microbiol Immunol Infect 2006;39:335-341.